Shares of TG Therapeutics Inc (NASDAQ:TGTX) have been given an average recommendation of “Buy” by the nine brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $27.75.

Several equities research analysts have recently issued reports on the stock. B. Riley reissued a “buy” rating and issued a $27.00 price objective (up previously from $21.50) on shares of TG Therapeutics in a research report on Friday, March 9th. BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, March 6th. Zacks Investment Research raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 16th. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Tuesday, January 16th.

How to Become a New Pot Stock Millionaire

TG Therapeutics (NASDAQ:TGTX) traded down $0.13 during trading on Friday, hitting $15.97. 433,923 shares of the stock traded hands, compared to its average volume of 1,627,414. TG Therapeutics has a 52 week low of $7.25 and a 52 week high of $17.35. The firm has a market capitalization of $1,209.28, a price-to-earnings ratio of -8.43 and a beta of 1.40.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46). TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 145.58%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. sell-side analysts anticipate that TG Therapeutics will post -1.68 earnings per share for the current year.

In related news, CFO Sean A. Power sold 32,006 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the completion of the sale, the chief financial officer now directly owns 517,464 shares of the company’s stock, valued at approximately $4,398,444. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 16.70% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Teacher Retirement System of Texas acquired a new stake in TG Therapeutics during the 4th quarter valued at $151,000. MetLife Investment Advisors LLC acquired a new position in TG Therapeutics during the 4th quarter worth $172,000. Ellington Management Group LLC acquired a new position in TG Therapeutics during the 4th quarter worth $203,000. First Mercantile Trust Co. grew its holdings in TG Therapeutics by 28.6% during the 4th quarter. First Mercantile Trust Co. now owns 26,701 shares of the biopharmaceutical company’s stock worth $219,000 after acquiring an additional 5,938 shares in the last quarter. Finally, Voya Investment Management LLC grew its holdings in TG Therapeutics by 40.2% during the 2nd quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 6,463 shares in the last quarter. 50.63% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/tg-therapeutics-inc-tgtx-given-consensus-rating-of-buy-by-brokerages/1956852.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.